Sanofi eyes 'moonshot' drug acquisitions to offset upcoming Dupixent patent loss
Sanofi's CFO Francois-Xavier Roger told Fierce that the company is looking at 'moonshot' treatments as potential acquisition targets to rebuild its pipeline.
The push comes as the U.S. patent on Dupixent, Sanofi's blockbuster immunology drug, is set to expire in 2031, creating a revenue gap the company wants to fill.
Roger said Sanofi will pursue external growth through business development and M&A, focusing on late-stage and commercial medicines in its core disease areas while also considering early-stage projects.
He added that more details will be shared by year-end, but cautioned that a major deal is not expected in the next two months.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Sanofi considering ‘moonshot’ treatments as M&A targets to survive Dupixent patent cliff”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that